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Aim:  Regulatory approval of biosimilars often depends on extrapolating evidence from one clinical 
indication to all of those of the originator biologic.  We aimed to develop a quantitative benefit-risk 
analysis to assess whether the resulting increase in the uncertainty in the clinical performance of 
biosimilars (i.e. risk) may be countered by their lower pricing (benefit). 
Methods: A one-year decision-analytic model was developed for the biosimilar infliximab (Inflectra®) 
for Crohn’s disease. The perspective was that of the NHS in the UK and costs were valued to 2015/16.  
A hypothetical cohort of biologic-naïve patients with moderate-to-severe Crohn’s disease were 
simulated through the model.  Immunogenicity to infliximab was a key modifier, influencing rates of 
non-response and infusion reactions.  Net health benefit was estimated based on quality-adjusted life 
years (QALYs).  A range of sensitivity analyses tested the robustness of the results and explored how 
the biosimilar price must respond to varying immunogenicity to remain the preferred option.   
Results: The base-case analysis predicted a positive incremental net health benefit of 0.04 (95% 
Central Range 0.00-0.09) favouring the biosimilar, based on 0.803 QALYs, and costs of £18,087 and 
£19,176 for biosimilar and originator, respectively.  Two-way sensitivity analyses suggested that if 50% 
of patients developed antibodies, the value-based price of £410 per vial must be lower than that of 
the originator (£420), but remain higher than the actual market price (£378).   
Conclusions: The model supports the use of Inflecta® for Crohn’s disease in the UK, and provides a 
framework for the quantitative evaluation of biosimilars in the context of health technology 
assessment.  Value-based pricing using this methodology could protect health systems from the 





Key points for decision makers 
 The base-case analysis predicts a positive incremental net health benefit of 0.04 (95% Central 
Range 0.00-0.09) favouring the biosimilar and suggests that if 50% of patients developed 
antibodies, the value-based price would need to be below the originator but higher than the 
current market price. 
 The study presents a novel framework for the quantitative benefit-risk assessment of 
biosimilars, illustrated with biosimilar infliximab for Crohn’s disease 
 The methods provide an explicit framework for balancing risks (the uncertainty in the efficacy 





As patents for biological therapies expire, biosimilars, which are near identical versions of the 
originator products, are changing the therapeutic landscape [1].  Biosimilars are generally less 
expensive, or prompt a reduction in the price of the originator products while achieving comparable 
health outcomes.  Medicines regulators seek assurance that there are no clinically meaningful 
differences in efficacy and safety to the originator [2,3].  This normally requires clinical trial evidence 
from a population sensitive to potential differences in efficacy, safety, or immunogenicity between 
the biosimilar and originator.  Evidence of similarity in one clinical indication is assumed to extrapolate 
to other indications for which the originator product is approved based on the totality of the evidence, 
including the structural, physicochemical, functional, and non-clinical data in addition to clinical 
studies [2,3].   
Biosimilars are not intended to be superior to the originator (these would be biobetters [4]) but there 
is a risk of an inferior safety profile (if only marginally).  Uncertainties regarding the safety of 
biosimilars at the point of marketing authorisation are inherently related to the use of non-inferiority 
trials to justify near-equivalence of efficacy, the absence of trial evidence for all indications due to the 
process of extrapolation, and the lack of long-term experience and data [5,6].  The primary reason for 
adopting biosimilars and acceptance of the potential risks with no improved health benefits is the 
opportunity for cost savings.  The biosimilar market in the US alone is forecast to save $54 billion in 
direct spending on biologic drugs from 2017 to 2026 [7]. 
The first biosimilar anti-TNFα approved in the EU, following the patent expiry of originator infliximab 
(Remicade®), was Inflectra®. Marketing authorisation was based primarily on evidence relating to non-
inferiority in rheumatoid arthritis [8]; but regulatory experience with specific reference to Crohn’s 
disease (CD) has been mixed, with some countries initially rejecting the drug or limiting its approved 
indications [9–11]. A key concern was that CD patients are more likely than others to develop 
antibodies to infliximab (ATI), which trials in other indications were unable to rule out [12,13].  The 
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consequences of developing ATI (immunogenicity) include reduced efficacy and increased likelihood 
of adverse events, particularly infusion reactions, which are rare but can be severe. Even minor 
differences between the biosimilar and originator have the potential to cause significant harm for 
patients [14]. 
With each new biosimilar, heath care payers therefore face the question of whether the cost savings 
can justify the increased uncertainty in their clinical performance.  Health economic modelling can be 
used as part of the health technology assessment to evaluate the benefit-risk balance by pooling the 
available evidence and reflecting uncertainty in inputs, to estimate the likelihood of a biosimilar 
providing a net health gain [15].  The incremental net health benefit (INHB) between the biosimilar 
and originator represents the added value of the biosimilar considering both the reduced costs and 
the increased uncertainty surrounding its clinical performance given societal resource constraints [16] 
and, in effect, represents a quantitative approach to the benefit-risk assessment of biosimilars. 
This analysis aimed to quantitatively assess the benefit-risk balance of biosimilar infliximab versus 
originator, to determine whether the cost savings justify the increased uncertainties in efficacy and 
safety, and to assess the value of conducting further trials in CD to reduce uncertainty in key 
parameters. The results are discussed in the context of emerging evidence from clinical use and 
ongoing trials in CD. 
2. Methods 
2.1. Model structure 
We constructed a decision analytic model (decision tree) to compare the benefits and risks of 
infliximab (IFX) biosimilar and originator.  We adapted a model of one-year cost-effectiveness of 
infliximab dose escalation versus initiation of adalimumab [17], identified from a MEDLINE review, by 
the addition of adverse events.  A hypothetical cohort of 100,000 biologic-naïve 35-year-old 70-kg 
patients with moderate-to-severe CD was simulated through the model (Figure 1), which was 
structured over 4-weekly intervals.  The perspective of the analysis was that of the National Health 
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Service (NHS) in the UK.  For the purposes of the economic analysis, costs were restricted to those of 
the National Health Service (NHS) in the UK.  Although CD is a chronic condition, a one-year time-
horizon was justified, as the analysis focused on short-term outcomes. 
Due to the concern regarding immunogenicity, the development of antibodies to infliximab (ATI) is an 
important modifier in the model, influencing the rate of primary and secondary non-response [18], 
and the likelihood of infusion reaction.  Acute or severe infusion reactions take place within 24 hours 
of infusion, and delayed infusion reactions take place between 24 hours and 14 days after infusion 
[19].  In line with common practice [20], the disease states were defined by the Crohn’s Disease 
Activity Index (CDAI): moderate-to-severe disease equates to a CDAI score ≥220, remission to a score 
<150 and response to a reduction in CDAI score ≥70 points, resulting in mild disease (≥150 CDAI score 
<220). 
All patients entered the model in period 1 in moderate-to-severe disease state and received IFX 
therapy of 5mg/kg at weeks 0, 2 and 6, with infusions every eight weeks for those who respond, in 
accordance with the summary of product characteristics [21].  Initial response and the development 
of ATI were measured at week 12 (period 4). Those with no initial response ceased treatment with 
IFX, moved to standard care therapy in period 4, initially remaining in moderate-to-severe disease 
state.  Standard care included all other possible therapies and surgeries [22].   
Patients with primary response were in a mild disease state during periods 2 and 3 and entered ATI 
status-dependent remission or mild disease states in period 4.  IFX maintenance therapy continued 
every 8 weeks unless they experienced secondary non-response (loss of response), or a severe 
infusion reaction, upon which they moved to standard care.  Patients who experienced secondary 
non-response did so from a mild disease state.  Acute and delayed infusion reactions were managed 
in the same period and IFX was not withdrawn.  Patients could only experience one infusion reaction 
over the year and all were assumed to be in period 4, following the 4th infusion, consistent with the 
findings of the pivotal clinical trial of maintenance infliximab (ACCENT I) [23]. 
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At the end of one year, patients who remained on IFX could be in remission or experiencing mild 
disease or had moved to standard care or died.  Patients receiving standard care could end the year 
in a moderate-to-severe disease state or post-surgical remission.  Death in the model could result from 
age-specific, all-cause mortality, severe infusion reaction (SIR), surgery or disease flare.  Age-specific, 
all-cause mortality [24] was applied during week 12, meaning none had experienced maintenance 
therapy. 
Moves to alternative treatment or surgery occurred at the end of each period to allow for benefits, 
harms and costs to be allocated in whole periods. The impact of treatment benefits and harms were 
represented as utilities, from which quality-adjusted life years (QALYs) could be estimated. The effects 
of IFX treatment (and other biologics in scenarios) occur within the period of treatment. Standard care 
is assumed to take two periods to have effect [17].  Secondary non-response is assumed to take place 
at 38 weeks in line with the median in patients receiving the standard therapy of 5mg/kg of infliximab 
from ACCENT I [23]. The effect of IFX was assumed to wash out 19 weeks after stopping IFX due to a 
severe infusion reaction, in line with the median time to offset of response during placebo 
maintenance in ACCENT I [23].  
The model was constructed in Microsoft Excel using visual basic language for probabilistic sensitivity 
analysis. 
2.2. Model parameters 
We obtained parameter estimates for ATI development, efficacy, adverse events, health utilities and 
costs from targeted MEDLINE literature reviews of clinical trials and previous cost-effectiveness 
models. All searches included the terms “Crohn’s disease” and “infliximab”, as well as other relevant 
terms depending upon the parameter, for example “loss of response”, “antibodies” and “drug 
sensitivity/or infusion reaction”.   Model inputs are shown in Table 1. 
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2.2.1. ATI development 
The rate of ATI development for Remicade (ATI_R) during maintenance use was taken from a meta-
analysis [25] as ACCENT I had 46% inconclusive samples and was considered potentially biased [23]. 
In the base case, this is also the ATI development rate for Inflectra (ATI_I). 
2.2.2. Efficacy 
Early IFX clinical trials focused on single infusions, and the pivotal maintenance trial, ACCENT I, 
included only those who had responded to an initial infusion.  To provide an estimate of the induction 
phase response, the probability of response at 12 weeks was taken from an observational study [26].   
The rates of loss of response (LOR) by ATI status were derived from a meta-analysis of the impact of 
antibodies on clinical outcomes [27].  Rates of remission and response by ATI status at 1 year were 
calculated by adjusting the rates calculated by Saito et al [28] proportionately by the LOR probabilities.  
The probabilities of outcomes for standard care were derived from a cohort study by Silverstein et al 
[17,29].  Patients were divided between the surgery and moderate-to-severe disease outcomes in 
proportion to the ratio between the probabilities in Kaplan et al [17] (Table 1).   
2.2.3. Adverse events 
The probabilities of infusion reactions by ATI status were calculated from a meta-analysis of the impact 
of antibodies on the risk of infusion reactions, with supplementary data from its lead author [30].  Data 
on mortality from serious adverse events were used for the calculation of associated risk [28]. 
2.2.4. Utilities 
Utility values for disease states and surgery were taken from published cost-effectiveness models 
[31,32], based upon utility scores defined by Gregor et al [33] using a standard gamble approach. 
Acute and delayed infusion reactions do not affect disease activity but a 0.01 utility decrement was 
applied per event [34]. In the absence of other utility estimates, we made the following assumptions: 
utility for a severe infusion reaction equalled that for surgery; and post-surgical utility equalled 
moderate-to-severe disease for one period, then surgical remission for the remainder of the year. 
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2.2.5. Resource use 
Patients receiving IFX (and other biologics) also receive standard care. We assumed no vial sharing so 
each infusion required 4 vials and an NHS day case hospital attendance [35].  Acute infusion reactions 
were managed at the time of infusion within the day case hospital attendance.  Delayed infusion 
reactions required an additional outpatient clinic visit.  Severe infusion reactions were assumed to 
require a 4 night hospital stay, based on a study of another biologic agent [36], which aligns with a 
long stay non-elective hospital admission.  We assumed that post-surgical therapy was in line with 
standard care resource use for moderate-to-severe disease. 
2.2.6. Costs 
Standard care costs were taken from a previous Markov model, inflated using the retail price index 
[35,37]. The prices of all biologics were from the British National Formulary (BNF) [38–40]. The costs 
of day-case hospital attendances, outpatient clinic visits and long stay non-elective admissions were 
from contemporary NHS reference costs [35]. All costs are in pounds Sterling (£). 
2.3. Outcomes 
Estimates of efficacy, development of ATI and adverse events for Inflectra were assumed equivalent 
to Remicade in the base case analysis, in line with the assumption of biosimilarity.  The outcomes of 
the analyses were 1-year costs and QALYs for treatment, and the proportion of patients who: 
experienced sustained remission for 12 months, remission, no adverse events following IFX treatment 
for 12 months, moved to standard care, developed ATIs, non-response (primary and secondary), 
infusion reactions (acute, delayed and serious) and surgeries.   
Comparative value was determined from the Incremental Net Health Benefit (INHB), which is the 
difference in Net Health Benefit (NHB) between each intervention [16]. INHB was calculated as the 
incremental benefit (in QALYs) of the biosimilar compared with the originator, minus the incremental 
cost divided by the threshold for cost-effectiveness:  
Equation 1: Incremental net health benefit (INHB) 
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𝐼𝑁𝐻𝐵 = (𝐸𝐼 − 𝐸𝑅) − (𝐶𝐼 − 𝐶𝑅)/λ 
Where E and C are the expected benefit (QALY) and costs for Inflectra (I) and Remicade (R), 
respectively, and λ is the cost-effectiveness threshold for a QALY (assumed £30,000) [41].   
2.4. Sensitivity analyses 
One-way deterministic analyses were performed for all variables to determine the thresholds over 
which the risks associated with biosimilar therapy outweigh the benefits, indicated by a negative INHB.  
Where available, ranges were based on confidence intervals, otherwise we assumed plausible ranges.  
The results were presented in a tornado plot to examine the impact on INHB. 
A two-way sensitivity analysis was conducted to assess the interaction between the development of 
ATI_I and the price differential between the two drugs.  This identifies the discount in vial price 
required to compensate for a higher rate of antibodies to Inflectra.  
A probabilistic sensitivity analysis (PSA) with 10,000 Monte Carlo draws from distributions was 
conducted. All parameters were included in the PSA except the following fixed costs: Inflectra and 
Remicade vial costs and NHS costs for short-stays, long-stays and day cases. Efficacy, adverse event 
and utility parameters were drawn from beta distributions; Dirichlet distributions were used for 
related parameters (i.e. disease state and outcomes of standard care); and costs for surgery and 
disease state-related standard and supportive care were drawn from gamma or lognormal 
distributions (Table 1).  We assumed that the unknown biosimilar standard deviations for the rate of 
initial response and development of ATI were 50% higher than the originator drug to reflect the 
uncertainty in efficacy and immunogenicity. 
2.5. Scenario analyses 
To test the robustness of the assumptions in the base case, we considered seven scenarios with 
alternative assumptions (Table 2).  Patients in scenarios (v) to (vii) all have a washout period of six 
weeks prior to starting a second biologic whereupon they receive standard care.  Standard care is 
continued when starting the new therapy, under the same assumptions of the base case.  Patients 
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who switch following a severe infusion reaction continue their response to IFX until it is lost at week 
33.   However, an improvement in disease course prompted by the second biologic will override the 
IFX response.  Patients who change biologic following primary or secondary non-response experience 
moderate-to-severe disease during the washout period and until the new therapy takes effect.  LOR 
for UST and VED was assumed to occur in line with IFX.  Adverse events were not modelled for the 
second-line biologics. 
Initial response rates to ADA at week 12 in the IFX failure population were taken from an open label 
trial as the best match for the dose and timing of outcomes [45], and no LOR was assumed over the 
year [46].  Initial response to UST at 16 weeks, and sustained remission at 44 weeks, were based on a 
clinical trial for UST in the IFX failure population [47,48].  The initial response for VED was taken from 
GEMINI-3, a pivotal study of induction therapy in anti-TNFα failure patients [49].  The week 10 
response rate was used as a week 14 rate was unavailable.  Sustained remission in anti-TNFα failure 
patients at week 52 was from a study that used licensed doses of VED [50].  The GEMINI-3 ratio of 
week 10 response to remission was applied to the long-term remission to calculate long-term 
response. 
UST and VED infusions use single vials and require a day case hospital attendance.  ADA and UST 
subcutaneous injections are patient-administered and are assumed to require no additional resource. 
2.6. Value of information analysis 
A value of information analysis was conducted using the Sheffield Accelerated Value of Information 
(SAVI) [51] to identify the value of reducing uncertainty in the model. This was used to assess the value 
of conducting further clinical research. We calculated the annual expected value of perfect 
information (EVPI) per patient, and the annual and 10-year population EVPI estimated based on the 
number of patients affected by Crohn’s disease each year in England [52].  A partial EVPI analysis 





We did not apply a discount rate to the model results, as they did not extend beyond a year. A discount 
rate of 3.5% per annum was applied to the population EVPI. 
2.8. Model validation 
We performed model validation by: (i) systematically checking the model formulae and inputs; (ii) 
conducting a number of sensitivity analyses using null and extreme values to ensure results were in 
the expected direction and within plausible limits; and (iii) comparing the clinical end points from the 
model with source data. 
2.9. Reporting 
The analysis is reported in line with the Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) statement [53]. 
3. Results 
3.1. Base case 
The base case analysis results in expected one-year QALYs of 0.803 for both Inflectra and Remicade, 
with expected one-year costs of £18,087 (USD 25,109) and £19,176 (USD 26,620), respectively (Table 
3).  The additional benefit of Inflectra to society, based solely on the reduced cost of Inflectra as the 
health outcomes are equivalent, is represented in the 0.04 (95% Central Range 0.00-0.09) incremental 
net health benefit (INHB) versus Remicade.  Clinical outcomes for both treatments are shown in Table 
3.  
3.2. Sensitivity analyses 
One-way sensitivity analyses demonstrated that the model was most sensitive to the Inflectra vial 
price and initial response rates of Inflectra and Remicade (Figure 2).  The INHB was stable for most 
model parameters, which were able to take extreme values without altering the result that Inflectra 
has a positive benefit-risk profile.  The INHB advantage of Inflectra was outweighed in the model only 
when the vial price exceeded that of Remicade. 
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A two-way sensitivity analysis of the base case (Figure 3) shows how the Inflectra vial price would need 
to adjust in response to increasing rates of developing ATI in order for it to remain the preferred 
choice.  Based on a cost-effectiveness threshold of £30,000 per QALY [40], and assuming 50% of 
patients develop ATI for Inflectra (ATI_I), compared with 12.4% who develop ATI from Remicade 
(ATI_R), then 57.7% of patients would switch to standard care after experiencing a serious infusion 
reaction or secondary non-response and, within that, 18% of patients would have a surgery.  Inflectra 
remained the preferred option provided it is priced below £410 per vial (compared with £420 for 
Remicade).  Even in a worst-case scenario of all patients developing ATI, resulting in 75% of patients 
moving to standard care and 23% having surgeries, a vial of Inflectra could be priced up to £395 and 
it would remain the treatment of choice with a positive INHB (Figure 3, base case). 
3.3. Probabilistic sensitivity analyses 
The probabilistic sensitivity analyses indicated that Inflectra had a positive INHB in 97.6% of 
simulations, and this result was robust over a range of threshold values.  Inflectra dominated 
Remicade in 50.4% of simulations and was less effective but less costly in 45.4% of simulations.  
Inflectra was more effective but more costly in 3.4% and was dominated by Remicade in 0.9% of 
simulations.  The net-benefit plane [53] illustrating the joint distribution of incremental costs and 
QALYs (Figure 4) shows the clustering of simulations on the vertical axis due to the minimal differences 
in QALYs between the two interventions. 
3.4. Scenario analyses 
Inflectra is associated with a positive INHB across the scenarios tested, with the exception of scenario 
(i) where the price of Remicade is reduced by 25% (Table 3).  Changes in INHB overall were minimal 
and, in fact, there was no change in INHB in scenarios involving a shorter wash-out of IFX following a 
SIR (iii), a shorter time to loss of response in patients with ATI (iv) and a switch to another biologic 
before standard care, (v), (vi) and (vii), as changes affected both biologics equivalently.   
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The results of the two-way sensitivity analysis reveal the value-based price for Inflectra as they identify 
the price at which the biosimilar could be marketed based upon the development of ATI and 
downstream consequences [55].  Most scenarios follow a similar pattern to the base case analysis 
(Figure 3). The price of Inflectra must reduce as ATI_I increases, to remain the optimal choice, but 
remains below the current market price at all risks of ATI development.  Only in scenario (vii), where 
patients switch to vedolizumab after IFX failure, is a reduction to below the current market price 
necessary to remain the optimal choice, and it does so when 60% of Inflectra patients develop ATI. 
The relationship is reversed in scenario (iv) and the price of Inflectra can increase as ATI_I risk 
increases, due to the expected cost savings from the earlier movement to standard care. The cost 
reduction outweighs the QALY reduction, giving Inflectra an even greater net benefit than in the base 
case.  For illustration, when all Inflectra patients develop ATI, the expected QALY gain is 0.03 less than 
for Remicade whilst resulting in a cost saving of £1,029.  A similar pattern is seen for scenario (v) when 
patients switch to ADA after IFX failure.  In this case, the introduction of a second biologic reduces 
costs as it is cheaper than IFX, but also reduces the number of patients moving to standard care in the 
model and therefore limits the number of expensive surgeries as ATI_I increases.   
3.5. Value of information analysis 
Using the results of the probabilistic sensitivity analysis (PSA), the expected value of perfect 
information (EVPI) in the base case analysis is £7.56 per patient.  Based on the number of patients 
expected to be eligible for Inflectra in England (7,912) [52], the value of removing the decision 
uncertainty is £59,775 for one year and £807,332 for the assumed 20-year therapeutic lifetime of the 
drug.  This represents the upper limit on the investment of conducting further research to eliminate 
uncertainty in model parameters. A more informative expected value of partial perfect information 
(EVPPI) indicates that there would be no gain from any research to reduce uncertainty in any individual 
parameters, including the ATI rate of Inflectra. 
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The result of the second VOI analysis, where the price of Remicade is reduced to match that of 
Inflectra, provides a different result.  In this case, the EVPI increases to £220.51 per person, equivalent 
to £25.4 million (discounted) for the 20-year assumed therapeutic lifespan.  The EVPPI is now relevant 
and the highest value is for the initial response rate of Inflectra, where the expected value of reducing 
uncertainty is £196.42 per patient, which is £1.6 million per year, or £22.6 million over 20 years.  There 
is greater value in reducing uncertainty from a range of parameters, including the initial response rate 
of Remicade, and the rates of sustained remission, sustained response and loss of response in patients 
who do not develop ATI, than in reducing uncertainty in ATI_I, which has an EVPPI of £7.00 per patient. 
3.5. Model validation 
Systematic checks did not reveal any errors in formulae and inputs.  The sensitivity analyses 
demonstrated the model behaved as expected.    The clinical endpoints from the model aligned with 
source data. 
4. Discussion 
This is the first study to explicitly consider the trade-off between the risk of development of ATI (which 
is largely unknown at the time of marketing authorisation) and cost advantages of biosimilars, and the 
value of obtaining further evidence. It positions the problem of assessing the benefit-risk of biosimilars 
in the context of an economic evaluation framework.  For Inflectra, the results support the 
extrapolation process of regulators which deemed the new drug biosimilar to the originator [9,10].  
Non-inferiority of the biosimilar to the originator infliximab was demonstrated in a phase III trial for 
rheumatoid arthritis [8] and extrapolation assumes equivalence in efficacy for Crohn’s disease. Results 
from a post-marketing trial of Inflectra and Remicade indicate there is no significant difference 
between the efficacy and safety of the two drugs at 6 weeks [56].  Observational studies and clinical 
case series have confirmed that Inflectra appears to be safe and efficacious, especially in infliximab-
naïve patients [57]. A study of cross immunogenicity identified that ATI developed in patients treated 
with Remicade react to the biosimilar, further supporting the case that the two drugs are biosimilar 
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[58]. More recently, a phase 3, non-inferiority randomised controlled trial demonstrated no notable 
differences in the efficacy, pharmacokinetics, pharmacodynamics, safety, or immunogenicity of 
Inflectra and Remicade in the recruited population [59]. 
A major strength of our study is the transparency the approach provides for assessing the value of 
biosimilars, taking into account both benefits (in terms of cost savings) and the uncertainty of potential 
harms.  Biosimilars are promoted as suitable alternatives to originator products to restrain healthcare 
costs; however, the HTA of biosimilars presents significant challenges due to the assumption of 
equivalence in outcomes and the lack of availability of comprehensive data at the time of marketing 
authorisation. Our approach overcomes some of these difficulties by making explicit reference to, and 
characterising the uncertainty of ATI development as the driver for differences in treatment 
outcomes. This addresses potential areas of concern relating to the extrapolation exercise while 
allowing for the uncertainty to be quantified – both in terms of identifying whether the cost savings 
are sufficient for a health-care payer to accept a potentially inferior product, and the value of 
conducting further research [60].  This is especially relevant in the UK system where biosimilars are 
not subjected to health technology appraisal, but instead existing guidance for originator drugs is 
applied to the biosimilar once they have gained marketing approval [61]. 
By their nature, models that draw from multiple sources of evidence require many assumptions.  We 
were unable to locate evidence linking the risk of cancer or serious infection to ATI development so 
they were not considered, despite their importance in infliximab use and the likelihood of large cost 
and utility impacts. Estimates for ATIs were based on the episodic use of infliximab or were 
complicated by the absence of a standard definition of ATI, the many factors that can affect ATI test 
result [12] and the increasing recognition of transient ATI, which are idiosyncratic and have little 
impact on outcomes [62].  No recognition of the relation between ATI concentration and response 
was made; and factors other than ATI, which are recognised as predictors of response to infliximab in 
Crohn’s disease [63], including drug clearance, were not considered.  However, immunogenicity 
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appears to be the main factor associated with low drug concentrations long term, and may therefore 
be captured sufficiently in our sensitivity analyses.  Further limitations stemmed from the data 
available on “standard care” for Crohn’s disease, which do not accurately reflect current clinical 
management of CD and which we attempted to overcome by including scenarios with other biologics 
(adalimumab, vedolizumab and ustekinumab).  However, other scenarios might include dose 
escalation or shortening the interval between infusions prior to switching to another drug or a switch 
to the originator drug [20].  Further, modelling of second line biologics should consider their harms so 
as not to overstate their benefits.  Addressing some of these points might explain some of the 
counterintuitive results in the scenarios where increasing risk of immunogenicity with Inflectra can be 
accompanied with a justified increase in price because switching to alternative therapies is seen as 
more cost-effective.  However, accepting these limitations may be appropriate for a model focused 
not on predicting outcomes, but rather to offer a transparent and structured way to examine a 
complex decision problem.  
5. Conclusion 
In summary, in the absence of trial evidence, the model provides a basis for the quantitative 
evaluation of biosimilars to support health technology assessment.  Value-based pricing using this 
methodology would be possible to protect health systems such as the NHS in the UK from the potential 
risks of biosimilars where they are untested in the populations for which they have been approved. 
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Figure 1: Partial schematic representation of the decision-analysis model comparing Inflectra and 
Remicade. Standard care arm shown in offset box. Abbreviations: ATI – Antibodies to infliximab, LOR 
– loss of response 
Figure 2: Tornado plot of univariate analysis. Panel presents the ten parameters that led to the 
greatest change in overall incremental net health benefits (INMB).  Inflectra parameters (suffixed _I), 
Remicade parameters (suffixed _R).  L/H refer to lower and higher limits of parameter estimates.  
Abbreviations: ATI – Antibodies to infliximab, LOR – loss of response, IR – infusion reaction 
Figure 3: Results of the two-way analysis of risk of Inflectra antibodies (ATI) against incremental vial 
price.  Each figure represents a scenario. Scenario (i), 25% reduction in vial cost of Remicade; 
Scenario (ii), patients with secondary non-response but no adverse events continue treatment; 
Scenario (iii), 8 week infliximab wash out period; Scenario (iv), secondary non-response at 15 weeks 
for those developing ATI; Scenario (v), switch to adalimumab after IFX failure; Scenario (vi), switch to 
ustekinumab after IFX failure; and Scenario (vii), switch to vedolizumab after IFX failure. 
Figure 4: Net-benefit plane resulting from probabilistic sensitivity analysis.  The line represents the 




Table 1: Clinical event rates, health state utilities assigned to clinical events, and costs 







analysis Ref. low high 
Antibodies to infliximab (ATI) probability      
ATI development during maintenance usea 0.124 0.108 0.141 
Beta_R(95,19) 
Beta_I(6,1) [25] 
Efficacy transition probabilities          
Initial response to infliximab at 12 weeksb 0.833 0.667 1 
Beta_R(195,1383) 
Beta_I(84,594) [26] 
ATI+ responders in remission at 12 months 0.21 N/A N/A Dir(30) [27,28] 
ATI+ responders in response at 12 months 0.121 N/A N/A Dir(18) [27,28] 
ATI+ responders lost response at 12 monthsb 0.669 0.535 0.803 Dir(97) [27] 
ATI- responders in remission at 12 months 0.482 N/A N/A Dir(187) [27,28] 
ATI- responders in response at 12 months 0.278 N/A N/A Dir(108) [27,28] 
ATI- responders lost response at 12 monthsb 0.24 0.192 0.288 Dir(93) [27] 
Adverse event transition probabilities          
ATI+ responders experience acute IRb 0.315 0.252 0.378 Beta(78.170) [30] 
ATI+ responders experience delayed IRb 0.054 0.043 0.065 Beta(7,122) [30] 
ATI+ responders experience severe IRb 0.094 0.075 0.113 Beta(10,96) [30] 
ATI- responders experience acute IRb 0.142 0.114 0.17 Beta(133,804) [30] 
ATI- responders experience delayed IRb 0.021 0.017 0.025 Beta(12,569) [30] 
ATI- responders experience severe IRb 0.061 0.049 0.073 Beta(3,46) [30] 
Death from severe IRc 0.004 0 0.01 Beta(2,609) [28] 
Age-specific all-cause mortalityc 0.001 0 0.005 Beta(1,630) [24] 
Adalimumab therapy      
12 week remission rate 0.29   N/A [44] 
12 week response rate 0.39   N/A [44] 
12 week no response rate 0.41   N/A [44] 
Ustekinumab therapy      
Initial response at week 16 0.474    [46] 
Responders in remission at week 44 0.386    [47] 
Responders in response at week 44 0.312    [47] 
Responders lost response at week 44  0.302    [47] 
Vedolizumab therapy      
Initial response at week 10     [48] 
Responders in remission at week 52 0.280    [48,49] 
Responders in response at week 52 0.213    [48,49] 
Responders lost response at week 52 0.507    [48,49] 
Standard care therapy d      
   
Remain moderate-to-severe disease 0.680  0.544 0.816 Dir(30) [17,29] 
Require surgeryb 0.312 0.250 0.375 Dir(14) [17,29] 
Death from surgery 0.002 N/A N/A Beta(96,63831) [17,29] 
Death from Crohn's disease flare 0.008 N/A N/A Dir(0.3) [17,29] 
Quality of life utilities          
Medical remissione 0.89 0.67 1 Beta(11,1) [31,32] 
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analysis Ref. low high 
Mild diseasee 0.81 0.61 1 Beta(12,3) [31,32] 
Moderate-to-severe diseasee 0.74 0.56 0.93 Beta(15,5) [31,32] 
Surgerye 0.4 0.3 0.5 Beta(36,55) [31,32] 
Surgical remissione 0.8 0.6 1 Beta(11,3) [31,32] 
Severe infusion reactione 0.4 0.3 0.5 Beta(36,55) [31,32] 
Utility decrement per acute or delayed IRc 0.01 0 0.1 Beta(0.1,14) [33] 
Death 0 N/A N/A   
Costs (GBP)          
Inflectra vial costf 378 189 420 N/A   
Remicade vial cost 420 N/A N/A N/A [37] 
Adalimumab subcutaneous injection cost 358 N/A N/A N/A [37] 
Ustekinumab vial & subcutaneous injection cost 2,147 N/A N/A N/A [38] 
Vedolizumab vial cost 2,050 N/A N/A N/A [39] 
Infusion (day case hospital attendance) 697 N/A N/A N/A [34] 
Remission therapy (4 weeks) e 58 43 72 Lognormal(4.1,0.1) [34,36] 
Mild disease therapy (4 weeks) e 165 123 206 Gamma(61.5,2.7) [34,36] 
Moderate-to-severe disease therapy (4 weeks) e 257 193 321 Gamma(61.5,4.2) [34,36] 
Post-surgery therapy (4 weeks)g 257 129 386 Gamma(15.4,16.7) [34,36] 
Surgerye 11,116 8,337 13,894 Gamma(61.5,180.9) [34,36] 
Delayed IR (outpatient hospital attendance) 135 N/A N/A N/A [34] 
Severe IR (non-elective long stay admission) 2,581 N/A N/A N/A [34,35] 
 Note: 
Parameter values are identical in the base case for both treatments due to the assumption of biosimilarity.    
IR: infusion reaction. 
ATI+ patients who developed antibodies to infliximab 
ATI- patients who did not develop antibodies to infliximab 
_R indicates distribution for Remicade parameter and _I for Inflectra parameter 
 
a reported confidence interval used as range 
b reported mean +/-20% used as range 
c range determined by authors 
d Silverstein standard care outcomes with remission and response parameters shared proportionately between moderate to severe disease 
and surgery outcomes to reflect more severe disease pathway. 
e reported mean +/- 25% used as range  
f BNF reported prices, range of 50% to 100% of Remicade price 







Table 2: Scenario analyses. 
 
Scenario Assumption tested 
(i) 25% reduction in the price of Remicade® in response to the biosimilar 
entrance to the market. 
(ii) Patients who had not experienced any adverse event continuing with IFX 
despite secondary non-response, and remaining in the moderate-to-severe 
disease state. 
(iii) Shorter washout period of 8 weeks in those who experienced a severe 
infusion reaction and stopped IFX therapy. 
(iv) Shorter time to loss of response (LOR) in patients who developed ATIs (lower 
quartile of the interquartile range from ACCENT I) [23] to reflect the potential 
for increased clearance of the drug due to antibodies. 
(v) Patients switch to adalimumab (ADA) upon IFX failure.  Therapy begins with 
an 80mg subcutaneous injection in week 0, followed by 40mg in week 2 and 
every other week as per the product label [41].  Initial response is checked at 
week 12 and patients transition to standard care if no response. 
(vi) Patients switch to ustekinumab (UST) upon IFX failure.  UST is infused at an 
initial dose of 6mg/kg, with further therapy (90mg) administered 
subcutaneously at week 8 and every subsequent 12 weeks [42].  Initial 
response is checked at week 16 and patients transition to standard care if no 
response [42]. 
(vii) Patients switch to vedolizumab (VED) upon IFX failure.  VED is administered 
as 300mg infusions at weeks 0, 2 and 6, followed by maintenance infusions at 
week 14 and every 8 weeks after [43].  Initial response is checked at week 14 




Table 3: Model results for base case and scenarios. 
  


























Vial cost Inflectra  £  378   £  378  £  378  £  378  £  378  £  378   £  378  £  378 
Remicade  £  420   £  315   £  420  £  420  £  420  £  420   £ 420   £  420 
Expected QALY Inflectra 0.803 0.803 0.803 0.802 0.801 0.816 0.811 0.813 
Remicade 0.803 0.803 0.803 0.802 0.801 0.816 0.811 0.813 
Expected cost Inflectra  £  18,087   £  18,087  £  18,729   £  18,097   £  17,821   £ 18,166   £ 19,421   £ 21,366  
Remicade  £  19,176   £  16,453   £  19,867   £  19,187   £  18,890   £ 19,255   £ 20,511   £ 22,455  
Net health 
benefit 
Inflectra 0.200 0.200 0.179 0.199 0.207 0.211  0.164  0.101  
Remicade 0.164 0.254 0.141 0.162 0.172 0.174  0.128  0.064  
Incremental QALY 0.000  0.000  0.000  0.000  0.000  0.000  0.000  0.000  
Cost -£  1,089   £  1,634  -£ 1,138  -£ 1,089  -£ 1,069  -£  1,089  -£  1,089  -£  1,089  
NHB 0.036 -0.054 0.038 0.036 0.036 0.036  0.036  0.036  
Vial cost -£  42   £   63  -£  42  -£  42  -£  42  -£  42  -£  42  -£  42  
ICER Dominant Dominated Dominant Dominant Dominant Dominant Dominant Dominant 
Clinical outcomes Sustained remission 35.0% 35.0% 35.0% 35.0% 35.0% 35.7% 35.4% 35.7% 
Remission 48.9% 48.9% 48.9% 48.9% 48.9% 50.1% 43.2% 51.3% 
IFX for 12 months with no AEs 44.8% 44.8% 62.2% 44.8% 44.8% 44.8% 44.8% 44.8% 
Standard care 44.8% 44.8% 27.5% 44.8% 44.8% 18.4% 29.9% 27.7% 
Developed ATIs 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 
Primary non-response 16.6% 16.6% 16.6% 16.6% 16.6% 16.6% 16.6% 16.6% 
Secondary non-response 24.4% 24.4% 24.4% 24.4% 24.4% 24.4% 24.4% 24.4% 
Deaths 0.5% 0.5% 0.5% 0.5% 0.5% 0.2% 0.2% 0.2% 
Acute infusion reactions 13.6% 13.6% 13.6% 13.6% 13.6% 13.6% 13.6% 13.6% 
Severe infusion reactions 5.4% 5.4% 5.4% 5.4% 5.4% 5.4% 5.4% 5.4% 
Delayed infusion reactions 2.1% 2.1% 2.1% 2.1% 2.1% 2.1% 2.1% 2.1% 
28 
 
Surgeries 14.0% 14.0% 14.0% 14.0% 14.0% 2.8% 3.6% 3.6% 
Note: Scenario (i), 25% reduction in vial cost of Remicade; Scenario (ii), patients with secondary non-response but no AEs continue treatment; Scenario (iii), 8 week IFX 
wash out period; Scenario (iv), secondary non-response at 15 weeks for those developing ATIs; Scenario (v), patients switch to adalimumab before standard care; Scenario 
(vi), patients switch to ustekinumab before standard care; Scenario (vii), patients switch to vedolizumab before standard care.  
Abbreviations: QALY - quality adjusted life year; NHB - net health benefit; ICER - incremental cost effectiveness ratio; IFX – infliximab; AEs - adverse events; ATI - antibodies 






































Repeated as per 
remission (12 months)
ATI negative Repeated as per ATI positive
No response - standard care
Death (age specific all-cause)
Standard 
care
No 
response
Surgery
Death
Surgical 
remissionDeath 
(flare)
30 
 
31 
 
 
  
32 
 
 
